Dr. Joaquin M. Espinosa's lab at the University of Colorado Denver focuses on understanding and improving the lives of individuals with Down syndrome through innovative research. The lab investigates auditory dysfunction in Down syndrome, aiming to identify the underlying causes of hearing loss and assess therapeutic interventions. Additionally, the team explores Down Syndrome Regression Disorder (DSRD), studying potential treatments and their biological mechanisms.

Dr. Ellen J. Hess's lab at Emory University studies dystonia, a condition that causes involuntary muscle contractions. Their research focuses on understanding why dystonia is more common in females and how hormonal differences might influence the disease. By using advanced mouse models, the lab aims to determine the genetic and physiological factors contributing to sex differences in dystonia, which could lead to better diagnoses and treatments in the future.

Benson Edagwa's lab focuses on creating innovative, long-acting drug formulations for the treatment of pediatric patients with HIV-1. Their main goal is to develop a six-month injectable antiretroviral therapy that improves adherence to treatment. By using advanced drug delivery methods, they aim to overcome the limitations of daily oral therapies, making it easier for children to receive life-saving HIV treatment.

Dr. John D Imig's lab studies how certain molecules in the body, called epoxyeicosatrienoic acids (EETs), can help regulate blood flow and kidney function. They focus on how kidney damage, caused by things like lack of blood flow or blockages, can lead to long-term health issues like high blood pressure and chronic kidney disease. The lab uses techniques in genetics and pharmacology to explore how increasing levels of EETs can potentially prevent or restore kidney function and protect against high blood pressure.

Dr. Tally Marie Milnes' research lab at the University of Arizona focuses on understanding how the endocannabinoid system can be targeted to treat conditions related to opioid use and headaches. The lab explores innovative approaches to investigating opioid-induced respiratory depression and migraine symptoms, combining techniques from pharmacology and molecular biology. Their work aims to develop new therapeutic strategies that could enhance current treatments for pain and opioid overdose management.

Dr. Shuo Xiao's lab at Rutgers focuses on understanding how certain environmental chemicals and chemotherapy drugs affect female reproductive health. Their research investigates the harmful effects of per- and polyfluoroalkyl substances (PFAS), known for their persistence in the environment, on ovarian function. Additionally, they explore the mechanisms through which cancer treatments cause ovarian damage and potential strategies to protect women's fertility during cancer therapy.

Dr. Jared Brown's lab at the University of Colorado Denver focuses on understanding how certain environmental exposures, particularly silica from burning agricultural crops, contribute to chronic kidney disease. His research also explores the role of mast cells in lung injury caused by chemical pollutants. By investigating these critical health issues, the lab aims to develop predictive models and potential treatments for diseases related to environmental toxins.

Dr. Tatiana G Kutateladze's lab studies how certain chemical changes in the molecular structure of DNA and proteins, known as epigenetic modifications, influence aging and diseases like Alzheimer's. Their research focuses on a specific modification on histones, the proteins that package DNA, and how this impacts gene expression and cellular function. By understanding these processes, the lab aims to find new ways to prevent or treat age-related disorders.

Dr. Robert Clinton Barber's research focuses on understanding how epigenetic changes, specifically DNA methylation patterns, affect the onset and progression of Alzheimer's disease (AD) in different populations, particularly Mexican Americans and non-Hispanic whites. By analyzing data from a large cohort study, his lab aims to uncover significant biological markers related to cognitive decline and health disparities in Alzheimer's disease. This work not only seeks to advance our scientific understanding of AD but also aims to improve health outcomes in diverse communities.

Dr. Samie Jaffrey's lab at Weill Medical College focuses on understanding how chemical modifications in RNA molecules influence gene expression and cellular behavior, particularly in the context of cancer and neuronal function. The lab employs innovative techniques to map and analyze these modifications, contributing to the emerging field of epitranscriptomics. Through interdisciplinary collaboration and advanced methodologies, the lab seeks to unravel the complex regulatory mechanisms governing RNA and its impact on health and disease.

Dr. Jingchuan Guo's lab focuses on improving diabetes care by ensuring equitable access to the latest glucose-lowering medications for socially disadvantaged patients. With a strong emphasis on data analysis and machine learning, the lab aims to identify patient groups who would benefit most from these treatments and develop strategies to enhance their healthcare outcomes. By examining the intersection of health equity and economic evaluation, the lab works to bridge the gap in diabetes care for those at higher risk of complications.

Dr. Roberta Brinton's lab at the University of Arizona focuses on understanding how estrogen affects brain health, particularly during the transition to menopause. The research investigates the impact of aging and hormonal changes on the brain's energy systems and their implications for diseases like Alzheimer's. By studying these mechanisms, the lab aims to find ways to prevent or delay cognitive decline in aging women due to hormonal changes.

Dr. Alessandro Fatatis's lab at Drexel University focuses on understanding how certain cancer cells thrive in the harsh environment of metastatic prostate cancer, especially when traditional therapies targeting the Androgen Receptor fail. They explore the role of Interleukin-1beta, a signaling molecule that may help cancer cells survive and spread in bone tissue. Through their research, they aim to uncover new treatment strategies that could complement existing therapies and combat advanced prostate cancer more effectively.

Dr. Hui Feng's lab studies neuroblastoma, a type of cancer that affects children, particularly focusing on how certain proteins influence immune responses in tumors. They investigate how MYCN, a gene often associated with cancer aggressiveness, contributes to a hostile tumor microenvironment that suppresses the immune system. By understanding these mechanisms, the team aims to develop better immunotherapy strategies to fight neuroblastoma and possibly other cancers.

Dr. Kathryn M Ferguson's lab at Yale University focuses on understanding how the environment of cells, specifically the membranes they are part of, affects the behavior and structure of integral membrane proteins (IMPs). This research is critical because many drugs target these proteins, but we often don't fully understand how they work. By using innovative technologies and interdisciplinary collaboration, the lab aims to reveal how these proteins function and interact with their surrounding membranes.

Dr. Carrie Ferrario's research lab at the University of Michigan focuses on understanding how food-related cues influence cravings and eating behavior, particularly in the context of obesity. The lab studies the brain's reward systems and how junk food can alter neural circuits, contributing to an enhanced craving for food in obese individuals. By using preclinical models, the lab aims to uncover the biological mechanisms that drive obesity and develop targeted prevention and treatment strategies.

Dr. Christopher Peter Ford's lab focuses on understanding how dopamine signals contribute to movement and learning processes in the brain. By studying the mechanisms of dopamine transmission, the research aims to determine how these signals impact motor activities and their dysfunction in conditions like Parkinson's disease. The lab employs innovative methods to explore different dopamine release patterns and their effects on behavior, striving for insights that could lead to improved treatments for motor disorders.

Dr. Heide L. Ford's lab focuses on understanding the mechanisms behind aggressive pediatric cancers like Rhabdomyosarcoma (RMS) and Triple Negative Breast Cancer (TNBC). Their research aims to uncover how specific transcription factors influence tumor growth and differentiation, potentially leading to targeted therapies that minimize toxicity. By combining advanced genetic tools and animal models, the team seeks to develop better treatments for these challenging cancers.

Dr. Tanya S. Freedman's lab at the University of Minnesota focuses on understanding the roles of two isoforms of the Lyn kinase, LynA and LynB, in immune signaling and their implications in autoimmune diseases like systemic lupus erythematosus (SLE). The research highlights how these isoforms interact differently in myeloid cells, which are crucial in the immune response. By studying these isoforms, the lab aims to uncover new therapeutic strategies for managing autoimmune conditions, particularly their effects in males and females.

Dr. Nancy Elizabeth Freitag's lab studies the bacteria Listeria monocytogenes, which can cause serious infections, especially in pregnant women. The research focuses on understanding how certain strains of this bacterium invade the placenta and affect fetal development. By uncovering the mechanisms behind this infection, the lab aims to improve infection management and maternal-fetal health outcomes.